[HTML][HTML] Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a …
FJ Lavalle-González, A Januszewicz, J Davidson… - Diabetologia, 2013 - Springer
Aims/hypothesis The aim of this work was to evaluate the efficacy and safety of canagliflozin
vs placebo and sitagliptin in patients with type 2 diabetes who were being treated with …
vs placebo and sitagliptin in patients with type 2 diabetes who were being treated with …
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
JPH Wilding, G Charpentier, P Hollander… - … journal of clinical …, 2013 - Wiley Online Library
Aims Canagliflozin is a sodium glucose co‐transporter 2 inhibitor developed for the
treatment of type 2 diabetes mellitus (T2 DM). This randomised, double‐blind, placebo …
treatment of type 2 diabetes mellitus (T2 DM). This randomised, double‐blind, placebo …
Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
HW Rodbard, J Seufert, N Aggarwal… - Diabetes, Obesity …, 2016 - Wiley Online Library
Aims To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co‐
transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately …
transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately …
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a …
WT Cefalu, LA Leiter, KH Yoon, P Arias, L Niskanen… - The Lancet, 2013 - thelancet.com
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in
patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the …
patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the …
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week …
G Schernthaner, JL Gross, J Rosenstock… - Diabetes …, 2013 - Am Diabetes Assoc
OBJECTIVE To evaluate the efficacy and safety of canagliflozin, a sodium glucose
cotransporter 2 inhibitor, compared with sitagliptin in subjects with type 2 diabetes …
cotransporter 2 inhibitor, compared with sitagliptin in subjects with type 2 diabetes …
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
T Forst, R Guthrie, R Goldenberg, J Yee… - Diabetes, Obesity …, 2014 - Wiley Online Library
Aim The efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor,
was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with …
was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with …
Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis
XP Yang, D Lai, XY Zhong, HP Shen… - European journal of …, 2014 - Springer
Purpose To assess the efficacy and safety of the novel sodium glucose co-transporter 2
(SGLT2) inhibitor—canagliflozin for type 2 diabetes (T2DM). Methods A search of Medline …
(SGLT2) inhibitor—canagliflozin for type 2 diabetes (T2DM). Methods A search of Medline …
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a …
LA Leiter, KH Yoon, P Arias, G Langslet, J Xie… - Diabetes …, 2015 - Am Diabetes Assoc
OBJECTIVE To assess the efficacy/safety of canagliflozin, a sodium–glucose cotransporter 2
inhibitor, compared with glimepiride over 104 weeks in patients with type 2 diabetes …
inhibitor, compared with glimepiride over 104 weeks in patients with type 2 diabetes …
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea
L Ji, P Han, Y Liu, G Yang, NK Dieu Van… - Diabetes, Obesity …, 2015 - Wiley Online Library
Aims To evaluate the efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2
inhibitor, in Asian patients with type 2 diabetes mellitus (T2DM) inadequately controlled by …
inhibitor, in Asian patients with type 2 diabetes mellitus (T2DM) inadequately controlled by …
Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes
G Fulcher, DR Matthews, V Perkovic… - Diabetes, Obesity …, 2016 - Wiley Online Library
Aims To assess the efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2
(SGLT2) inhibitor, in patients with type 2 diabetes enrolled in the CANagliflozin …
(SGLT2) inhibitor, in patients with type 2 diabetes enrolled in the CANagliflozin …
相关搜索
- efficacy and safety diabetes mellitus
- safety of canagliflozin background metformin
- safety of canagliflozin sitagliptin in patients
- metformin and sitagliptin titrated canagliflozin
- metformin and sulphonylurea canagliflozin in patients
- efficacy and safety canagliflozin in subjects
- metformin and sitagliptin diabetes mellitus
- safety of canagliflozin meta analysis
- diabetes mellitus canagliflozin in patients
- asian patients metformin in combination
- efficacy and safety background metformin
- efficacy and safety canagliflozin in patients
- efficacy and safety sitagliptin in patients
- safety of canagliflozin metformin and sulphonylurea
- efficacy and safety titrated canagliflozin
- safety of canagliflozin diabetes mellitus